Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Oncopeptides CEO Sofia Heigis was recently interviewed by Richard Ramanius, equity analyst at Redeye, on the topic of the 2024 year-end report published on February 27. Richard Ramanius asks questions about the fourth quarter, including sales, potential license agreements and financing.
Watch the interview via this link (requires free membership at Redeye) – in Swedish only.
